Adamis Announces Review of Strategic Alternatives
October 03, 2022 16:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in...
Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
September 21, 2022 07:30 ET
|
Adamis Pharmaceuticals Corporation
Interim data from the Phase 2/3 clinical trial of Tempol did not demonstrate statistical significance of its primary endpoint of clinical resolution of COVID-19 symptoms at day 14 versus placebo ...
Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects
September 12, 2022 16:05 ET
|
Adamis Pharmaceuticals Corporation
The clinical trial of Tempol has reached the initial planned enrollment of 248 subjects Independent Data Monitoring Board to review interim data from approximately 200 initial subjects SAN DIEGO,...
Adamis Pharmaceuticals Announces Results of Annual Meeting of Stockholders
August 12, 2022 17:00 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its 2022 Annual Meeting of Stockholders (“Annual Meeting”) was convened, as...
Adamis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 10, 2022 16:02 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
Adamis Pharmaceuticals Schedules Second Quarter 2022 Financial Results Conference Call and Corporate Update
August 08, 2022 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
July 29, 2022 08:00 ET
|
Adamis Pharmaceuticals Corporation
ISS Recommends Stockholders Support Key Proposals Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote (or Change Their Vote) is 11:59 p.m. PT on...
Adamis Pharmaceuticals Issues Letter to Stockholders
July 21, 2022 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Appoints Vickie Reed to Board of Directors
May 26, 2022 16:05 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s board of...
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
May 18, 2022 17:00 ET
|
Adamis Pharmaceuticals Corporation
David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE)...